12/24
09:02 am
incy
Incyte (NASDAQ:INCY) was given a new $103.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Incyte (NASDAQ:INCY) was given a new $103.00 price target on by analysts at Truist Financial Corporation.
12/23
07:51 pm
incy
?????·???????·?????????????????????????????????????????????????? [CNET News]
Low
Report
?????·???????·?????????????????????????????????????????????????? [CNET News]
12/23
09:37 am
incy
Is It Too Late To Consider Incyte After A 45% Rally In 2025? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Incyte After A 45% Rally In 2025? [Yahoo! Finance]
12/22
10:37 pm
incy
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance]
Low
Report
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance]
12/22
02:56 am
incy
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer [Yahoo! Finance]
Low
Report
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer [Yahoo! Finance]
12/22
02:44 am
incy
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Low
Report
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
12/22
02:42 am
incy
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
Low
Report
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
12/18
05:31 pm
incy
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally [Yahoo! Finance]
Medium
Report
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally [Yahoo! Finance]
12/18
08:00 am
incy
Incyte to Present at Upcoming Investor Conference
Low
Report
Incyte to Present at Upcoming Investor Conference
12/17
11:24 am
incy
UCB's Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights [Yahoo! Finance]
Low
Report
UCB's Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights [Yahoo! Finance]
12/17
11:20 am
incy
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Low
Report
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
12/15
11:40 am
incy
Is Incyte Stock Outperforming the Nasdaq? [Yahoo! Finance]
Low
Report
Is Incyte Stock Outperforming the Nasdaq? [Yahoo! Finance]
12/15
08:33 am
incy
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China [Yahoo! Finance]
Medium
Report
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China [Yahoo! Finance]
12/12
08:30 am
incy
Incyte Announces Change to its Board of Directors
Low
Report
Incyte Announces Change to its Board of Directors
12/11
01:28 pm
incy
Microsoft Corporation (MSFT) Presents at Barclays 23rd Annual Global Technology Conference Transcript [Seeking Alpha]
Low
Report
Microsoft Corporation (MSFT) Presents at Barclays 23rd Annual Global Technology Conference Transcript [Seeking Alpha]
12/9
08:11 am
incy
Incyte (NASDAQ:INCY) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
Low
Report
Incyte (NASDAQ:INCY) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
12/9
01:18 am
incy
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? [Yahoo! Finance]
Low
Report
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? [Yahoo! Finance]
12/8
09:37 pm
incy
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? [Yahoo! Finance]
Low
Report
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? [Yahoo! Finance]
12/8
04:30 pm
incy
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Low
Report
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
12/8
10:12 am
incy
Incyte (NASDAQ:INCY) was given a new $92.00 price target on by analysts at Morgan Stanley.
Low
Report
Incyte (NASDAQ:INCY) was given a new $92.00 price target on by analysts at Morgan Stanley.
12/8
08:12 am
incy
Incyte (NASDAQ:INCY) was given a new $121.00 price target on by analysts at Mizuho.
Medium
Report
Incyte (NASDAQ:INCY) was given a new $121.00 price target on by analysts at Mizuho.
12/8
07:22 am
incy
Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/7
09:30 am
incy
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
Medium
Report
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
12/7
09:30 am
incy
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
Medium
Report
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
12/6
09:07 am
incy
Incyte: Buy At This Inflection Point [Seeking Alpha]
Medium
Report
Incyte: Buy At This Inflection Point [Seeking Alpha]